The biological target of the study is a population of cells known as corpus cavernosum smooth muscle cells, or CCSMCs, which form the muscular scaffolding of the erectile tissue. During an erection, these cells must relax in a coordinated fashion to allow the spongy chambers of the penis to fill with blood, and their ability to do so depends on maintaining what biologists call a contractile phenotype, a differentiated state in which the cell is packed with the contractile proteins that respond to vascular signals. Under the chronic oxidative stress of diabetes, however, these cells can undergo what researchers term phenotypic switching, abandoning their contractile identity in favor of a synthetic state characterized by proliferation, migration and the production of extracellular matrix. In the synthetic state, the cells lose the very proteins, such as alpha-smooth muscle actin and smooth muscle myosin heavy chain, that give them their mechanical function, and they instead express markers like osteopontin and proliferating cell nuclear antigen. This transition is increasingly recognized as a pivotal event in the progression of diabetes-related erectile dysfunction, but the regulatory circuits that connect diabetic stress to this switch have remained poorly understood.

To probe those circuits, the team began by examining the corpus cavernosum of rats made diabetic through injection of streptozotocin, a chemical that selectively destroys insulin-producing cells and produces a model of type 1 diabetes widely used in erectile dysfunction research. In these animals, the researchers found that expression of ARHGAP10, a member of the Rho GTPase-activating protein family, was significantly reduced compared with healthy controls. ARHGAP10 is known to function as a brake on Rho GTPase signaling, a pathway that governs cytoskeletal dynamics and smooth muscle contraction, so its loss in diabetic tissue immediately suggested a possible contributor to the erosion of contractile function.

The researchers then tested whether restoring ARHGAP10 could reverse the damage. Using adenoviral vectors delivered directly into the erectile tissue, they overexpressed the Arhgap10 gene in the cavernous tissue of diabetic rats and assessed erectile function by measuring intracavernosal pressure relative to mean arterial pressure, the standard physiological readout of erection quality in rodent models. The results were striking: animals receiving the ARHGAP10 vector showed measurably improved erectile responses compared with diabetic controls, and molecular analysis of their cavernous tissue revealed a marked suppression of the synthetic phenotypic switch, with contractile markers preserved and synthetic markers held in check.

To understand how ARHGAP10 exerts these effects, the team turned to RNA sequencing of primary CCSMCs grown in the laboratory. This transcriptomic survey identified G0S2, the G0/G1 switch gene 2, as a key downstream effector of ARHGAP10. G0S2 is a small protein with established roles in cell cycle control and lipid metabolism, best known in other contexts for its interaction with adipose triglyceride lipase, but its involvement in smooth muscle phenotypic regulation had not been appreciated. Co-immunoprecipitation assays then confirmed that ARHGAP10 and G0S2 physically interact, forming a protein complex within the cells. This physical association proved to be more than a curiosity; it was the mechanistic linchpin of the entire pathway.

The connection to mitochondria emerged when the researchers examined the organelles themselves. Mitochondria are the power plants of the cell, and their functional state is routinely assessed by measuring membrane potential, the electrical charge across the inner mitochondrial membrane that drives energy production, along with the generation of reactive oxygen species, the chemically reactive molecules that accumulate when the electron transport chain falters, and the ultrastructural appearance of the organelles under transmission electron microscopy. In diabetic conditions, CCSMCs showed the classic signature of mitochondrial dysfunction: collapsed membrane potential, excessive mitochondrial reactive oxygen species production and damaged ultrastructure. Remarkably, restoring ARHGAP10, through its interaction with G0S2, rescued all three parameters, restoring membrane potential, taming the overproduction of mitochondrial ROS and improving the structural integrity of the organelles.

The causal chain was then tested from both directions. When the researchers knocked down G0S2 in cultured cells, the protective effects of ARHGAP10 on the contractile phenotype were abolished, demonstrating that G0S2 is necessary for ARHGAP10 to work. Conversely, when G0S2 alone was overexpressed in the cavernous tissue of diabetic rats, without any ARHGAP10 manipulation, the treatment effectively reproduced the therapeutic benefits of ARHGAP10, restoring erectile function and preserving the contractile phenotype of the smooth muscle cells. This sufficiency experiment is particularly significant because it elevates G0S2 from a mere correlate to a genuine therapeutic target, one that sits downstream of ARHGAP10 and could potentially be manipulated directly by drugs.

The clinical context of these findings is important. Current first-line therapy for erectile dysfunction consists of phosphodiesterase type 5 inhibitors, the drug class that includes sildenafil, which work by amplifying the nitric oxide signaling that drives blood flow into the penis. These drugs are effective for many patients, but a substantial fraction of men with diabetes respond poorly to them, largely because diabetes ravages the nerves, blood vessels and smooth muscle that the drugs depend upon. By targeting the underlying cellular degeneration rather than the downstream signaling, an ARHGAP10-G0S2-based strategy would represent a fundamentally different approach, one that aims to preserve or restore the contractile machinery of the erectile tissue itself rather than simply coax more blood through a failing system.

Several technical details of the study strengthen its conclusions. The use of both in vivo adenoviral gene delivery and in vitro primary cell culture allowed the team to triangulate their findings across experimental systems, and the comprehensive mitochondrial assessment, spanning membrane potential measured with the JC-1 fluorescent probe, reactive oxygen species quantification and transmission electron microscopy of organelle ultrastructure, provided converging evidence that mitochondrial rescue is the operative mechanism. The team also traced the pathway’s connection to canonical smooth muscle contraction signaling, examining the RhoA pathway and its downstream effector MYPT1, thereby situating ARHGAP10 within the broader Rho signaling architecture that governs smooth muscle tone. Supplementary experiments further showed that ARHGAP10 overexpression attenuates the proliferation and migration of CCSMCs induced by platelet-derived growth factor-BB, a potent driver of phenotypic switching, and that pharmacological knockdown of G0S2 promotes switching on its own, reinforcing the necessity of this gene for maintaining the contractile state.

As with any preclinical rodent study, the road from these findings to human therapy is long, involving the development of deliverable interventions, safety testing and clinical trials. Gene therapy approaches for erectile dysfunction have been explored for decades without reaching routine clinical use, and the adenoviral vectors employed here are research tools rather than ready-made medicines. Nevertheless, the identification of a necessary and sufficient downstream mediator in G0S2 offers a concrete molecular handle that small molecules or other modalities could eventually target. The work also adds to a growing appreciation that mitochondrial dysfunction is not merely a byproduct of diabetic tissue damage but an active driver of it, and that restoring mitochondrial health can reverse pathological cellular reprogramming. For the millions of men whose diabetes has eroded both their vascular health and their quality of life, the demonstration that a single protein interaction can restore erectile function in a disease model is a compelling proof of concept, and a reminder that some of the most promising advances in medicine come from following the molecular threads wherever they lead, even into the smallest organelles of the body’s most private machinery.

Subject of Research: The role of the ARHGAP10-G0S2 protein interaction in preserving mitochondrial function and contractile phenotype of corpus cavernosum smooth muscle cells to ameliorate diabetic erectile dysfunction

Article Title: ARHGAP10-G0S2 interaction attenuates phenotypic switching of corpus cavernosum smooth muscle cells by restoring mitochondrial function, thereby ameliorating erectile dysfunction in diabetic rats

Article References: Liao, Z.-Q., Luo, J.-Q., Xiang, Y.-R., Liu, Y.-H., Lu, B.-X., Luo, C.-Y., He, H.-Y., Zhou, X.-C., Pan, M.-X., He, S.-H., Wei, A.-Y., & Zhang, H.-B. (2026). ARHGAP10-G0S2 interaction attenuates phenotypic switching of corpus cavernosum smooth muscle cells by restoring mitochondrial function, thereby ameliorating erectile dysfunction in diabetic rats. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-08942-0

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08942-0

Keywords: erectile dysfunction, diabetes, ARHGAP10, G0S2, mitochondrial dysfunction, phenotypic switching, smooth muscle cells, corpus cavernosum, reactive oxygen species, diabetic rats, Journal of Translational Medicine, Rho signaling